NDAORALTABLET
Approved
Jun 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDERIDE-80/25 is a fixed-dose combination tablet containing propranolol hydrochloride (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic). This combination is indicated for the management of hypertension by reducing blood pressure through beta-adrenergic blockade and diuretic mechanisms. The drug targets patients requiring dual antihypertensive therapy for enhanced cardiovascular control.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%), suggesting brand team focus is on retention strategies and managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
INDERIDE-80/25 offers limited new career opportunities given its LOE-approaching status and minimal clinical activity. Roles focus on protecting market share, managing generic transition, and maximizing residual value rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on INDERIDE-80/25 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.